Synlogic (SYBX) Q2 2025 earnings summary

Executive summary

• Discontinued lead Phase 3 trial (Synpheny-3) for PKU in February 2024 after internal review indicated unlikely success; strategic alternatives including merger or sale are being actively pursued.

• Corporate restructuring reduced workforce to one full-time employee, with consultants supporting ongoing operations and strategic review.

• No product revenue generated; focus remains on maximizing shareholder value through potential transactions.

Financial highlights

• Net loss of $0.5 million for Q2 2025, compared to net income of $3.1 million in Q2 2024; net loss of $0.2 million for the six months ended June 30, 2025, versus $22.5 million loss in the prior year period.

• Research and development expenses dropped to $0.01 million in Q2 2025 from $2.2 million in Q2 2024, reflecting the discontinued trial and restructuring.

• General and administrative expenses decreased to $0.8 million in Q2 2025 from $1.2 million in Q2 2024 due to lower headcount and professional fees.

• Restructuring and other charges were a gain of $0.01 million in Q2 2025, compared to a $3.8 million gain in Q2 2024, mainly from asset sales and lease termination.

• Cash and cash equivalents were $17.0 million as of June 30, 2025, down from $19.8 million at year-end 2024.

Outlook and guidance

• Current cash and cash equivalents expected to fund operations at current levels for at least the next 12 months.

• Expenses anticipated to remain low in the near term as the company continues to evaluate strategic alternatives.

• No expectation of product revenue unless regulatory approval is achieved or a strategic transaction is completed.